<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704429</url>
  </required_header>
  <id_info>
    <org_study_id>PRN1008-005</org_study_id>
    <nct_id>NCT02704429</nct_id>
  </id_info>
  <brief_title>A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris</brief_title>
  <official_title>An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Principia Biopharma, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Principia Biopharma Australia Pty Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Principia Biopharma, a Sanofi Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label cohort study in adult patients with newly diagnosed or relapsing pemphigus&#xD;
      vulgaris, with intra-patient dose-adjustment based on clinical response and BTK occupancy,&#xD;
      and with conventional immunosuppressive &quot;rescue treatment&quot;, if indicated. The duration of&#xD;
      therapy in Part A will be 12 weeks, followed by 12 weeks of follow up. The extension phase,&#xD;
      Part B includes 24 weeks of therapy, followed by 4 weeks of follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      To evaluate the safety of PRN1008 in patients with pemphigus vulgaris (PV) To evaluate the&#xD;
      clinical activity of PRN1008 in patients with PV, per criteria in the European Academy of&#xD;
      Dermatology and Venereology (EADV) 2014 Pemphigus S2 Guideline (Hertl et al. 2015)&#xD;
&#xD;
      Secondary Objectives To evaluate the pharmacokinetics (PK) and the pharmacodynamics (PD) of&#xD;
      multiple doses of PRN1008 in patients with PV To evaluate the relationship of PK and PD to&#xD;
      each other and to efficacy and safety in this patient population&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 22, 2016</start_date>
  <completion_date type="Actual">January 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Part A with 12 weeks treatment and 12 weeks follow-up. Part B with 24 weeks treatment and 4 weeks follow-up.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Part A: 24 week treatment</time_frame>
    <description>The incidence of treatment-emergent adverse events (TEAEs), including clinically significant changes in physical examination, laboratory tests, and vital signs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Control of disease activity at 4 weeks</measure>
    <time_frame>4 weeks treatment</time_frame>
    <description>The proportion of subjects who are able to achieve control of disease activity (CDA) within 4 weeks of starting PRN1008 treatment without the need for doses of prednisone or prednisolone &gt;0.5 mg/kg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to control of disease activity (CDA)</measure>
    <time_frame>Part A: 12 week treatment; 12 week follow up and Part B: 24 week treatment, 4 week follow-up</time_frame>
    <description>Time to control of disease activity (CDA) defined in EADV 2015 Pemphigus S2 Guideline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to end of consolidation phase</measure>
    <time_frame>Part A: 12 week treatment; 12 week follow up and Part B: 24 week treatment, 4 week follow-up</time_frame>
    <description>Time to end of consolidation phase as defined in EADV 2015 Pemphigus S2 Guideline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete response</measure>
    <time_frame>Part A: 12 week treatment; 12 week follow up and Part B: 24 week treatment, 4 week follow-up</time_frame>
    <description>Time to complete response as defined in EADV 2015 Pemphigus S2 Guideline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse after PRN1008 treatment discontinuation</measure>
    <time_frame>Part A: 12 week follow up and Part B: 4 week follow-up</time_frame>
    <description>Time to relapse after PRN1008 treatment discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative corticosteroid usage</measure>
    <time_frame>Part A: 12 week treatment; 12 week follow up and Part B: 24 week treatment, 4 week follow-up</time_frame>
    <description>Cumulative corticosteroid usage</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Pemphigus Vulgaris</condition>
  <arm_group>
    <arm_group_label>PRN1008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Open-label PRN1008, 12 weeks; 12 week follow up; Part B: Open-label PRN1008, 24 weeks;4 weeks follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRN1008</intervention_name>
    <description>Part A: PRN1008, oral dose, 12 weeks; Part B: PRN1008, oral dose 24 weeks</description>
    <arm_group_label>PRN1008</arm_group_label>
    <other_name>BTK inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, aged 18 to 80 years old, with biopsy-proven, mild-moderate PV&#xD;
             (PDAI 8 to 45) in Part A and mild to severe PV in Part B (PDAI 8 to 60) that are&#xD;
             either:&#xD;
&#xD;
               -  newly diagnosed patients (i.e. naïve to an effective induction treatment regimen)&#xD;
                  for whom an initial period of PRN1008 monotherapy is judged clinically&#xD;
                  acceptable, or&#xD;
&#xD;
               -  relapsing patients, for whom an initial period of PRN1008 monotherapy, or&#xD;
                  combination therapy with any of low dose corticosteroid (≤ 10 mg/day),&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  A history of malignancy of any type, other than surgically excised non-melanoma skin&#xD;
             cancers or in situ cervical cancer within 5 years before the day of dosing&#xD;
&#xD;
          -  Use of immunologic response modifiers with the following periods prior to Day 1: 1&#xD;
             week: cyclophosphamide; 4 weeks: intravenous immunoglobulin, Kinaret (anakinra) and&#xD;
             Enbrel (etanercept); 12 weeks: Remicade (infliximab), Humira (adalimumab), Simponi&#xD;
             (golimumab), Orencia (abatacept), Actemra (tocilizumab), Cimzia (certolizumab),&#xD;
             Cosentyx (secukinumab), plasmapheresis; 6 months: Rituxan/MabThera (rituximab),&#xD;
             ofatumumab, any other anti-CD20 antibody, other long acting biologics&#xD;
&#xD;
          -  Use of &gt;10 mg per day of oral prednisolone per day within 2 weeks prior to Day 1&#xD;
             (inhaled and mucosal [for symptomatic treatment of oral lesions] corticosteroids are&#xD;
             allowed)&#xD;
&#xD;
          -  Use of proton pump inhibitor drugs such as omeprazole and esomeprazole&#xD;
&#xD;
          -  Has received any investigational drug (or is currently using an investigational&#xD;
             device) within the 30 days before receiving the first dose of study medication, or at&#xD;
             least 5 times the respective elimination half-life time (whichever is longer)&#xD;
&#xD;
          -  History of drug abuse within the precious 12 months&#xD;
&#xD;
          -  Alcoholism or excessive alcohol use, defined as regular consumption of more than&#xD;
             approximately 3 standard drinks per day&#xD;
&#xD;
          -  Refractory nausea and vomiting, malabsorption, external biliary shunt, significant&#xD;
             bowel resection that would preclude adequate study drug absorption&#xD;
&#xD;
          -  History of anorexia nervosa or periods of there months or more of low body weight&#xD;
             (BMI&lt;17.5)&#xD;
&#xD;
          -  Donation of a unit or more of blood or blood products within 4 weeks prior to Day 1&#xD;
&#xD;
          -  History of solid organ transplant&#xD;
&#xD;
          -  History of epilepsy or other forms of seizures in the last 5 years&#xD;
&#xD;
          -  Positive for screening for human immunodeficiency virus, hepatitis B (surface and core&#xD;
             antibodies unrelated to vaccination), or hepatitis C (anti-HCV antibody confirmed with&#xD;
             Hep C RNA)&#xD;
&#xD;
          -  History of active or latent tuberculosis (TB) infection (must test negative using the&#xD;
             QuantiFERON test to be eligible)&#xD;
&#xD;
          -  History of serious infections requiring intravenous (by catheter that delivers&#xD;
             antibiotics into your blood) treatment&#xD;
&#xD;
          -  Live vaccine within 28 days prior to baseline or plan to receive one during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dolca Thomas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Principia Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premier Specialists</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinclair Dermatology</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne, Dermatology Office</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinichki Bolnicki Centar Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <state>Siene-Saint Denis</state>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Ioannina</name>
      <address>
        <city>Ioánnina</city>
        <state>Ioannina</state>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Venereal and Skin Diseases A.Syggros</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papageorgiou General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2016</study_first_posted>
  <disposition_first_submitted>December 3, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>December 3, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 8, 2020</disposition_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

